Rebus Holdings, Inc. (RBSH)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 5000.00 USD | -99.3% |
| 2021 | 715 Thousand USD | 76.98% |
| 2020 | 404 Thousand USD | 1656.52% |
| 2019 | 23 Thousand USD | -93.72% |
| 2018 | 366 Thousand USD | 430.43% |
| 2017 | 69 Thousand USD | -90.6% |
| 2016 | 734 Thousand USD | -72.59% |
| 2015 | 2.67 Million USD | 1.86% |
| 2014 | 2.62 Million USD | -32.33% |
| 2013 | 3.88 Million USD | 50.99% |
| 2012 | 2.57 Million USD | -54.79% |
| 2011 | 5.69 Million USD | 47.6% |
| 2010 | 3.85 Million USD | 58.82% |
| 2009 | 2.42 Million USD | 243.41% |
| 2008 | 706.94 Thousand USD | 19.73% |
| 2007 | 590.43 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 9000.00 USD | 80.0% |
| 2023 Q1 | 5000.00 USD | 0.0% |
| 2022 FY | 5000.00 USD | -99.3% |
| 2022 Q3 | 134 Thousand USD | -49.43% |
| 2022 Q4 | 5000.00 USD | -96.27% |
| 2022 Q2 | 265 Thousand USD | -55.01% |
| 2022 Q1 | 589 Thousand USD | -17.62% |
| 2021 Q1 | 758 Thousand USD | 87.62% |
| 2021 FY | 715 Thousand USD | 76.98% |
| 2021 Q2 | 1.13 Million USD | 49.08% |
| 2021 Q3 | 995 Thousand USD | -11.95% |
| 2021 Q4 | 715 Thousand USD | -28.14% |
| 2020 Q3 | 33 Thousand USD | -71.55% |
| 2020 FY | 404 Thousand USD | 1656.52% |
| 2020 Q1 | 146 Thousand USD | 534.78% |
| 2020 Q2 | 116 Thousand USD | -20.55% |
| 2020 Q4 | 404 Thousand USD | 1124.24% |
| 2019 Q2 | 255 Thousand USD | -16.94% |
| 2019 Q4 | 23 Thousand USD | -67.14% |
| 2019 Q3 | 70 Thousand USD | -72.55% |
| 2019 Q1 | 307 Thousand USD | -16.12% |
| 2019 FY | 23 Thousand USD | -93.72% |
| 2018 Q2 | 49 Thousand USD | -14.04% |
| 2018 FY | 366 Thousand USD | 430.43% |
| 2018 Q4 | 366 Thousand USD | -5.91% |
| 2018 Q3 | 389 Thousand USD | 693.88% |
| 2018 Q1 | 57 Thousand USD | -17.39% |
| 2017 Q4 | 69 Thousand USD | -97.35% |
| 2017 Q3 | 2.6 Million USD | 2376.19% |
| 2017 Q2 | 105 Thousand USD | -57.49% |
| 2017 FY | 69 Thousand USD | -90.6% |
| 2017 Q1 | 247 Thousand USD | -66.35% |
| 2016 Q3 | 540 Thousand USD | -50.14% |
| 2016 Q1 | 1.76 Million USD | -33.98% |
| 2016 FY | 734 Thousand USD | -72.59% |
| 2016 Q2 | 1.08 Million USD | -38.74% |
| 2016 Q4 | 734 Thousand USD | 35.93% |
| 2015 Q2 | 312 Thousand USD | -81.41% |
| 2015 Q1 | 1.67 Million USD | -36.17% |
| 2015 FY | 2.67 Million USD | 1.86% |
| 2015 Q4 | 2.67 Million USD | 81.93% |
| 2015 Q3 | 1.47 Million USD | 371.79% |
| 2014 Q1 | 2.85 Million USD | -26.51% |
| 2014 Q3 | 3.85 Million USD | -24.26% |
| 2014 Q4 | 2.62 Million USD | -31.82% |
| 2014 Q2 | 5.09 Million USD | 78.32% |
| 2014 FY | 2.62 Million USD | -32.33% |
| 2013 FY | 3.88 Million USD | 50.99% |
| 2013 Q3 | 5.2 Million USD | 182.51% |
| 2013 Q2 | 1.84 Million USD | -35.52% |
| 2013 Q1 | 2.85 Million USD | 10.96% |
| 2013 Q4 | 3.88 Million USD | -25.3% |
| 2012 Q3 | 2.69 Million USD | -34.25% |
| 2012 Q1 | 5.06 Million USD | -11.01% |
| 2012 FY | 2.57 Million USD | -54.79% |
| 2012 Q4 | 2.57 Million USD | -4.55% |
| 2012 Q2 | 4.09 Million USD | -19.06% |
| 2011 Q1 | 7 Million USD | 81.62% |
| 2011 Q2 | 8.21 Million USD | 17.25% |
| 2011 FY | 5.69 Million USD | 47.6% |
| 2011 Q4 | 5.69 Million USD | -16.55% |
| 2011 Q3 | 6.82 Million USD | -16.94% |
| 2010 FY | 3.85 Million USD | 58.82% |
| 2010 Q4 | 3.85 Million USD | -5.67% |
| 2010 Q1 | 2.87 Million USD | 18.59% |
| 2010 Q2 | 4.66 Million USD | 61.93% |
| 2010 Q3 | 4.08 Million USD | -12.33% |
| 2009 FY | 2.42 Million USD | 243.41% |
| 2009 Q2 | 2.26 Million USD | 172.86% |
| 2009 Q4 | 2.42 Million USD | -16.56% |
| 2009 Q3 | 2.9 Million USD | 28.44% |
| 2009 Q1 | 830.18 Thousand USD | 17.43% |
| 2008 FY | 706.94 Thousand USD | 19.73% |
| 2008 Q4 | 706.94 Thousand USD | 0.0% |
| 2007 FY | 590.43 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -116.45% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 99.745% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 99.953% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 99.094% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.996% |
| Qrons Inc. | 420.00 USD | -1090.476% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 99.351% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.982% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 98.96% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.958% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.987% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 99.931% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | 93.452% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.995% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 99.651% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | 93.091% |
| Mesoblast Limited | 667.9 Million USD | 99.999% |
| Marizyme, Inc. | 22.01 Million USD | 99.977% |
| Genus plc | 1.02 Billion USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 99.632% |
| Pharming Group N.V. | 462.85 Million USD | 99.999% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 99.849% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 98.998% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 99.203% |
| ContraFect Corporation | 20.67 Million USD | 99.976% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 98.719% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 98.692% |
| IMV Inc. | 31.33 Million USD | 99.984% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 99.879% |
| MultiCell Technologies, Inc. | 126.22 USD | -3861.337% |
| ONE Bio Corp. | 70.08 Million USD | 99.993% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 99.468% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.996% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 98.842% |
| Q BioMed Inc. | 3.51 Million USD | 99.858% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.986% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 98.086% |
| Biomind Labs Inc. | 73.81 Thousand USD | 93.227% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.999% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 99.655% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.983% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 99.818% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 99.273% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 99.808% |
| GB Sciences, Inc. | 103.44 Thousand USD | 95.166% |
| Alpha Cognition Inc. | 2.45 Million USD | 99.796% |
| HST Global, Inc. | 1526.00 USD | -227.654% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 99.494% |
| Halberd Corporation | 10.13 Thousand USD | 50.647% |
| Enzolytics Inc. | 361.7 Million USD | 99.999% |
| Agentix Corp. | 261.39 Thousand USD | 98.087% |
| Resverlogix Corp. | 8.11 Million USD | 99.938% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 99.734% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.99% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 99.218% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | 78.052% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 99.944% |
| AVAX Technologies, Inc. | 7.37 Million USD | 99.932% |
| Zenith Capital Corp. | 7410.00 USD | 32.524% |
| Genscript Biotech Corporation | 3.38 Billion USD | 100.0% |
| Ember Therapeutics, Inc. | 184.00 USD | -2617.391% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 98.446% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 98.087% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 99.461% |
| Kadimastem Ltd | 2.3 Million USD | 99.783% |
| Helix BioMedix, Inc. | 3.02 Million USD | 99.835% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.991% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.966% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | 91.243% |
| LadRx Corporation | 2.3 Million USD | 99.783% |
| Cell Source, Inc. | 195.17 Thousand USD | 97.438% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 98.586% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 98.586% |
| NovAccess Global Inc. | 62.24 Thousand USD | 91.968% |
| Affymax, Inc. | 7.44 Million USD | 99.933% |
| Itoco Inc. | 1.4 Million USD | 99.643% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 94.773% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 95.283% |
| Mobile Lads Corp. | 52.00 USD | -9515.385% |
| CytoDyn Inc. | 11.13 Million USD | 99.955% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 96.503% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | 72.036% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 98.703% |
| SYBLEU INC | 330.46 Thousand USD | 98.487% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 98.779% |
| International Stem Cell Corporation | 5.39 Million USD | 99.907% |
| Bioxytran, Inc. | 137.63 Thousand USD | 96.367% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.967% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.97% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | 93.671% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 99.422% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 99.933% |
| Neutra Corp. | 2851.00 USD | -75.377% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.985% |
| PureTech Health plc | 693.97 Million USD | 99.999% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 99.938% |
| IXICO plc | 15.84 Million USD | 99.968% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 99.94% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.995% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.999% |